Objectives To evaluate the prevalence of late-onset neutropenia and its complications in patients treated with rituximab (RTX) for rheumatoid arthritis (RA) and other autoimmune diseases (AIDs) in a ...

cAMP is a universal second messenger that plays central roles in cardiovascular regulation influencing gene expression, cell morphology, and function. A crucial step toward a better understanding of ...

Lower rates of grade (Gr) ≥3 treatment-related adverse events (TRAEs) occurred with tarlatamab vs CTx (27% vs 62%); discontinuations due to TRAEs were lower with tarlatamab (3% vs 6%). The most common ...

Cyclic peptides have emerged as promising modulators of protein–protein interactions due to their unique pharmacological properties and ability to target extensive flat binding interfaces. However, ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

The initial publication acknowledged NSF CHE-1954325 for funding. The grant renewal was assigned a new number, NSF CHE-2247217, and the corrected acknowledgment should read as shown below. J.M.S. is ...

Despite this, rates of febrile neutropenia and sepsis did not differ between the arms. Patients had cytokine analyses done at baseline and after treatment, revealing that in patients with higher ...

The two treatment arms had a similar rate of grade 3 and 4 adverse events. The most common side effects in the durvalumab plus FLOT arm were diarrhea, nausea, neutropenia (low levels of white blood ...